Alnylam Pharmaceuticals is a biopharmaceutical company that develops and commercializes RNAi therapeutics, a drug class that silences messenger RNAs to prevent disease-causing proteins from being made, targeting genetically validated disease genes. The company markets multiple approved products including AMVUTTRA and ONPATTRO for transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria, while also earning royalties and milestone payments from partner-commercialized products like Leqvio and Qfitlia. Alnylam employs proprietary delivery technologies—including GalNAc conjugates, lipid nanoparticles, and advanced chemical platforms—to enable subcutaneous and intravenous administration, and maintains a pipeline of over 20 clinical programs targeting rare genetic diseases and prevalent conditions such as hypertension and hemophilia, with revenue generated through product sales, tiered royalties from collaborators including Sanofi and Novartis, and milestone-based partnerships with companies like Roche and Regeneron.